Functional significance of vitamin D receptor Foki polymorphism in human breast cancer cells

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Alimirah, Fatouma ^a,b   Peng, Xinjian ^a   Murillo, Genoveva ^a,b   Mehta, Rajendra G ^a,b  

^a ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

^b Illinois Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYCLOOXYGENASE 2; CYTOCHROME P450; CYTOCHROME P450 24A1; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN FOKL; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; STEROID MONOOXYGENASE; VITAMIN D; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CLONE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN STABILITY; BREAST TUMOR; FEMALE; GENETICS; INFLAMMATION; PATHOLOGY; START CODON; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CODON, INITIATOR; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; STEROID HYDROXYLASES; VITAMIN D;

EID: 79551564465     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016024     Document Type: Article

References (39)

1. Deeb KK, Trump DL, Johnson CS (2007) Vitamin D Signaling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7: 684-700.
2. Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, et al. (2009) High prevalence of Vitamin D deficiency despite supplementation in premenoupausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 27: 2151-2156.
3. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N (2009) Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27: 3757-3763.
4. Ellison TI, Eckert RL, MacDonald PN (2007) Evidence for 1,25-dihydroxyvitamin D3-independent transactivation by the vitamin D receptor: uncoupling the receptor and ligand in keratinocytes. J Biol Chem 282: 10953-10962.
5. Zinser GM, McEleney K, Welsh J (2003) Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol Cell Endocrinol 200: 67-80.
6. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, et al. (2001) Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 177: 145-159.
7. Trabert B, Malone KE, Daling JR, Doody DR, Bernstein L, et al. (2007) Vitamin D receptor polymorphisms and breast cancer risk in a large populationbased case-control study of Caucasian and African-American women. Breast Cancer Res 9: R84. doi:10.1186/bcr1833.
8. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, et al. (2004) Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res 10: 5472-5481.
9. Sinotte M, Rousseau F, Ayotte P, Dewailly E, Diorio C, et al. (2008) Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population. Endocr Relat Cancer 15: 975-983.
10. Chen WY, Berone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE (2005) Association between polymorphism in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14: 2335-2339.
11. McCullough ML, Stevens VL, Diver WR, Feigelson HS, Rodriguez C, et al. (2007) Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res 9: R9. doi:10.1186/bcr1642.
12. Raimondi S, Johansson H, Maisonneuve P, Gandini S (2009) Review and metaanalysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 30: 1170-1180.
13. Tang C, Chen N, Wu M, Yuan H, Du Y (2009) FokI polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 117: 391-399.
14. Alimirah F, Chen J, Xin H, Choubey D (2006) Androgen receptor autoregulates its expression by a negative feedback loop through upregulation of IFI16 protein. FEBS Lett 580: 1659-1664.
15. Whyte L, Huang YY, Torres K, Mehta RG (2007) Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res 67: 12007-12017.
16. Peng X, Jhaveri P, Hussain-Hakimjee EA, Mehta RG (2007) Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1a-hydroxyvitamin D5. Carcinogenesis 28: 1000-1007.
17. Jensen SS, Madsen MW, Lukas J, Bartek J, Binderup L (2002) Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D(3) among MCF-7 clones correlates with Vitamin D receptor protein induction. J Steroid Biochem Mol Biol 81: 123-133.
18. Turunen MM, Dunlop TW, Carlberg C, Väisänen S (2007) Selective use of multiple vitamin D response elements underlies the 1 alpha,25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene. Nucleic Acids Res 35: 2734-2747.
19. Kemmis CM, Salvador SM, Smith KM, Welsh JE (2006) Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136: 887-892.
20. Swami S, Krishnan AV, Feldman D (2000) 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6: 3371-3379.
21. Li XY, Boudjelal M, Xiao JH, Peng ZH, Asuru A, et al. (1999) 1,25- Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin. Mol Endocrinol 13: 1686-1694.
22. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, et al. (2000) The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 14: 401-420.
23. Pan MR, Hou MF, Chang HC, Hung WE (2008) Cyclooxygenase-2 upregulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer. J Biol Chem 283: 11155-11163.
24. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, et al. (2001) A potential role for Interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 58: 639-646.
25. Lu X, Kang Y (2009) Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284: 29087-29096.
26. Varfolomeev E, Vucic D (2008) (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 1: 1511-2111.
27. Hussain EA, Mehta RR, Ray R, Das Gupta TK, Mehta RG (2003) Efficacy and mechanism of action of 1a-hydroxy-24-ethyl-cholecalciferol (1a[OH]D5 in breast cancer prevention and therapy. Recent Results Cancer Res 164: 393-411.
28. Reichrath J, Rech M, Moeini M, Meese E, Tilgen W, et al. (2007) In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3 responsive and resistant melanoma cells. Cancer Biol Ther 6: 48-55.
29. Varshavsky A (1997) The N-end rule pathway of protein degradation. Genes Cells 2: 13-28.
30. Singh B, Berry JA, Vincent LE, Lucci A (2006) Involvement of IL-8 in COX-2- mediated bone metastases from breast cancer J Surg Res 134: 44-51.
31. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005-1009.
32. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
33. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH (2004) Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11: 309-316.
34. Zhang X, Zhu T, Chen Y, Hichem MC, Lee K, et al. (2003) Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem 278: 7580-7590.
35. Warren MA, Shoemaker SF, Shealy DJ, Bshar W, Ip MM (2009) Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice. Mol Cancer Ther. pp 2655-2663.
36. Kang JX, Liu J, Wang J, He C, Li FP (2005) The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells. Carcinogenesis 26: 1934-1939.
37. Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595-601.
38. Dalloul A (2009) CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev 8: 349-353.
39. Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, et al. (2009) Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci 100: 1668-1674.